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Bone mineral densitySI-591[N-[1-[[[(1S)-3-[[(3S)-hexahydro-2-oxo-1H-azepin-3-yl]amino]-1-(1-methylethyl)-2,3-
dioxopropyl]amino]carbonyl]cyclohexyl]-2-furancarboxamide] is an orally bioavailable compound thatwas syn-
thesized as one of several unique peptidomimetic compounds without a basic group. This compound was found
to have the ability to inhibit cathepsin K, a lysosomal cysteine protease. Cathepsin K is known to be expressed in
osteoclasts and involved in bone loss processes. In this study, SI-591 was shown to inhibit the activity of various
puriﬁed cathepsin molecules at nanomolar concentrations but had high selectivity for cathepsin K over other
subtypes including B and L. SI-591 also decreased the level of CTX-I, a bone resorption marker, which was re-
leased from osteoclasts in vitro in a dose-dependent manner. The mobilization of calcium from the bones to
the blood stream is known to increase in rats fed with a low calcium diet; SI-591 inhibited this increase in
serum calcium level at an oral dose of 3 mg/kg. Furthermore, SI-591 signiﬁcantly decreased the level of CTX-I
and DPD, bone resorptionmarkers, at oral doses of 10mg/kg or less in ovariectomized rats, while it did not affect
the level of BGP, a bone formationmarker. In addition, SI-591 prevented bonemineral density loss in the lumber
vertebrae and femurs in ovariectomized rats. These results suggest that SI-591 inhibits bone resorption without
affecting osteoblast maturation. Therefore, SI-591, a novel cathepsin K inhibitor, could be a promising agent for
the treatment of postmenopausal osteoporosis.
© 2015 Central Research Laboratories, Seikagaku Corporation. Published by Elsevier Inc. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Osteoporosis is a common age-related condition with signiﬁcant
morbidity and mortality that affects millions of people worldwide; the
incidence of this disorder is expected to increase even further as the
population ages. Osteoporosis is characterized by an imbalance be-
tween osteoblastic bone formation and osteoclastic bone resorption
and a decrease in bone mass. Such features are associated with in-
creased fractures, and are related to a reduced health-related quality
of life and an increased economic burden [1]. Therefore, it is crucial
that these fractures are diagnosed early and that speciﬁc treatment is
started as soon as possible. Currently, many treatments are available
for osteoporosis. Medical treatment options for reducing the risk ofosslinking telopeptide of type I
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eikagaku Corporation. Publishedosteoporotic fractures include the administration of adequate calcium,
vitamin D, and anti-osteoporotic medication such as bisphosphonates,
parathyroid hormone (PTH), raloxifene, and estrogen [2,3]. Additionally,
the US food and drug administration (FDA) has approved denosumab, a
fully human monoclonal antibody, for the treatment of postmenopausal
women who have a high risk for osteoporotic fractures. Among these
treatments, bisphosphonates are the most commonly prescribed drugs
for osteoporosis prevention as they both improve bone mineral density
and reduce fracture risk because of their strong inhibition of osteoclast
differentiation and bone resorption. However, bisphosphonates decrease
osteoblast proliferation and inhibit differentiation andmineralization [4].
Recent reports have shown that bisphosphonate therapy is associated
with atypical femoral fractures and osteoporosis of the jaw in long-term
osteoporotic treatment [5,6]. There is therefore a need for new treatment
options with high efﬁcacy, safety, and tolerability.
Cathepsin K is a lysosomal cysteine protease that is primarily re-
sponsible for bone resorption and remodeling and is highly expressed
in osteoclasts. The activity of cathepsin K degrades type I collagen,
which is the major structural component of bone, accounting for ap-
proximately 90% of the bone organic matrix [7–10]. Several studies of
cathepsin K knockout mice have been published; these represent a
model, which displays multiple osteosclerotic phenotypes due to an ab-
sence of bone resorption by the osteoclasts [11,12] as well as increasedby Elsevier Inc. This is an open access article under the CC BY-NC-ND license
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matrix metalloproteases 9 and 14 in the osteoclasts [13]. In humans,
pycnodysostosis is a rare autosomal recessive skeletal dysplasia caused
by amutation in the gene encoding cathepsin K, and is characterized by
short stature, osteosclerosis, acro-osteolysis, frequent fractures, and
skull deformities [14,15]. Therefore, many pharmaceutical companies
have become interested in cathepsin K as drug target and have designed
cathepsin K inhibitors that are predicted to be highly selective, safe, and
efﬁcient for osteoporosis therapy. One of these, Balicatib, is a basic pep-
tide mimic compound that has demonstrated a dose-dependent reduc-
tion in the biochemical markers of bone resorption, CTx and NTx, with
no change in bone formation markers in a clinical study [16]. However,
development of Balicatib was discontinued due to the occurrence of ad-
verse events (AEs), as skin rashes and rarer incidences of morphea-like
skin changes were observed [17,18]. It is possible that these AEs
were caused by including structures such as basic groups in the molec-
ular design of the currently available compounds [19,20]. On the
other hand, odanacatib proved effective in a late-stage clinical trial.
However, Merck announced there was some concern over safety
about odanacatib.
In this study, we synthesized a new type of cathepsin K inhibitor,
SI-591, which has hydrophilic and neutral properties. SI-591 showed a
high selectivity for cathepsin K and exerted remarkable inhibitory
effects on osteoclast-mediated bone resorption in vitro and on bone
density and bone resorption markers in rats.
2. Materials and methods
2.1. Compound
SI-591was synthesized at the Department of Central Research Labo-
ratories of Seikagaku Corporation, Japan (Fig. 1).
2.2. Materials
Recombinant human cathepsins S, B, and L were purchased from
Calbiochem (San Diego, CA, USA), recombinant human cathepsin K
was purchased fromMerck KGaA (Darmstadt, Germany), and recombi-
nant rat cathepsin K was prepared by Nosan Corporation (Kanagawa,
Japan). Z–Gly–Pro–Arg–MCA, Z–Val–Val–Arg–MCA, Z–Arg–Arg–MCA,
and Z–Phe–Arg–MCA were purchased from Peptides International
(Louisville, KY, USA). Calpeptin was purchased from Enzo Life Science,
Inc. (Farmingdale, NY, USA).
2.3. Animals
An effort was made to minimize discomfort and to reduce the num-
ber of animals used in this study. Animal experiments were conducted
with the approval of the Animal Experiment Ethics Committee of
Seikagaku Corporation, Shin Nippon Biochemical Laboratories Ltd. and
Ina Research Inc. in accordance with the Guidelines for Animal Experi-
mentation. Animal care and use were performed according to the indi-
vidual site guidelines and in compliancewith protocols approved by the
individual site Animal Experiment Ethics Committees.Fig. 1. Chemical structure of SI-591.2.4. Enzyme inhibitor assays
2.4.1. Cathepsin K assays
The enzyme inhibition assays of human and rat cathepsin K were
carried out according to a slightlymodiﬁedmethod of Brömme [21]. Ca-
thepsin K inhibition was determined using 30 μM Z–Gly–Phro–Arg–
MCAand recombinant human cathepsin K or recombinant rat cathepsin
K in l00 mMNa–K buffer (pH 4.5) containing 8 mM cysteine and 1 mM
EDTA for 30 min at 37 °C with SI-591 (ﬁnal concentration 1–3000 nM)
or the vehicle (ﬁnal concentration 0.5% DMSO). Reactionswere stopped
with 10 μM calpeptin. Cathepsin K activity was evaluated from the in-
crease in ﬂuorescence at Ex 355 nm/Em 460 nm using a multilabel
counter (ARVO SX, Perkin Elmer, Inc., Waltham, MA, USA). IC50 values
were calculated by numerical software (Origin 6.1 J, OriginLab. Co.,
Northampton, MA, USA).
2.4.2. Selectivity assays
To measure the enzyme activity of cathepsin B, L, and S, enzymatic
assays were carried out according to the slightly modiﬁed methods of
Brömme [22], McDonald [23], and Kirshke [24], respectively. Cathepsin
S inhibition was determined using 20 μM Z–Val–Val–Arg–AMC and re-
combinant human cathepsin S in l00 mM K phosphate buffer (pH 7.0)
containing 8 mM cysteine and 5 mM EDTA for 30 min at 37 °C with
SI-591 (ﬁnal concentration 0.1–300 nM) or the vehicle (ﬁnal concentra-
tion 0.5% DMSO). Cathepsin B inhibition was determined using 20 μMZ–
Arg–Arg–AMC recombinant human cathepsin B in l25 mM Na–K phos-
phate buffer (pH6.0) containing 8 mM cysteine and 1.25 mM EDTA for
30 min at 30 °C with SI-591 (ﬁnal concentration 1–3000 nM) or the
vehicle (0.5% DMSO). Cathepsin L inhibition was determined using
20 μMZ–Phe–Arg–MCA in l00mMrecombinant human cathepsin L sodi-
um acetate buffer (pH 5.5) containing 8mMcysteine and 5mMEDTA for
30min at 30 °Cwith SI-591 (ﬁnal concentration 1–3000 nM) or the vehi-
cle (ﬁnal concentration 0.5% DMSO). Reactions were stoppedwith 10 μM
calpeptin. Enzyme activity was evaluated from the increase in ﬂuores-
cence at Ex 355 nm/Em 460 nm using a multilabel counter (ARVO SX,
Perkin Elmer, Inc.). IC50 valueswere calculated bymathematical software
(Origin 6.1 J, OriginLab. Co.). The IC50 values were rounded to two signif-
icant digits.
2.5. Isolation of whole bone marrow cells
Pregnant female Sprague-Dawley (SD) rats were obtained from
Charles River Laboratories (Yokohama, Japan) on day 14 of gestation.
Osteoclasts were isolated from the tibias of 5-day old SD rats. Brieﬂy,
the tibias were aseptically removed and dissected free of adherent tis-
sues. The epiphyses were cut off with a scalpel blade and the marrow
cavity was ﬂushed with alpha minimum essential medium (α-MEM)
using a syringe with a 23-gauge needle. Unfractionated bone cells
were isolated from rat bones cultured overnight in α-MEM containing
5% fetal bovine serum (FBS) at 37 °C in 5% CO2.
2.6. Osteoclast formation and resorption assay
The osteoclast resorption assaywas carried out according to a slight-
ly modiﬁed method of Susa [25]. For the bone resorption assay, isolated
bone cells (500 μL, 1 × 105 cells/well) were plated and attached on ster-
ilized ivory slices (6mmdiameter, 300 μm thickness,Wako Pure Chem-
ical Industries, Ltd. (Osaka, Japan)) in α-MEM with 5% FBS in each well
of a 24-well plate. After overnight incubation at 37 °C in 5% CO2, the cells
were cultured in fresh medium supplemented with macrophage
colony-stimulating factor (M-CSF), 40 ng/mL receptor activator of nu-
clear factor κB ligand (RANKL), and SI-591 (0.01–10 μM) or the vehicle
(ﬁnal concentration 0.1% DMSO) for 3 days. On day 3, the mediumwas
exchanged with fresh medium containing cytokines and the test com-
pounds and cultured for a further 3 days. All cultures were maintained
at 37 °C in 5% CO2. On the 6 days of culture, the levels of bone-related
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medium using a human-speciﬁc Cross Laps ELISA assay (Nordic Biosci-
ence, Herlev, Denmark). The IC50 values were calculated from sigmoid
dose response curves using curve ﬁtting with computer software
(Origin 6.1 J, OriginLab. Co.).
2.7. TRAP staining
Osteoclast differentiationwas determined by stainingwith the oste-
oclast marker TRAP. After 6 days of culturing, TRAP-positive cells were
stained. Cells were washed in phosphate buffered saline (PBS), ﬁxed
in citrate solution with acetone and formaldehyde for 30 s and stained
for TRAP activity using a leukocyte Acid Phosphatase kit (Sigma-Aldrich,
St. Louis, MO, USA) according to the manufacturer's protocol.
2.8. Low-calcium diet-fed rat model
Male Wistar rats were purchased from Charles River Laboratories
and were allowed to acclimate for one week. After acclimation, the
rats were fed a low-calcium (0.05% calcium) diet and distilled water
ad libitum for oneweek. The ratswere divided into four groupsmatched
forweight (n=6 each). SI-591was administered orally at dose levels of
0 (control: 0.5 w/v% methylcellulose solution), 3, 10, and 30 mg/kg.
Blood samples of 400 μL from the jugular vein were drawn before and
at 4, 6, 24, h after administration. Serumwas obtained by centrifugation
(15 min, 3000 rpm, 4 °C). The serum concentrations of calcium were
measured using a CalciumC-test (Wako Pure Chemical Industries, Ltd.).
2.9. Surgically ovariectomized (OVX) rats
Female F344 rats were purchased from Charles River Laboratories
andwere allowed to acclimate for oneweek. The animalswere anesthe-
tized by an intravenous injection ofmixed anesthesia usingDormicum®
(Astellas Pharma Inc., Tokyo, Japan), Selactar® 2% (BayerHealthcare, Le-
verkusen, Germany.), Vetorphale® (Meiji Seika Pharma Co., Ltd., Tokyo,
Japan), and saline (1:2:1:2, 70 μL/body) into the tail vein. When it was
conﬁrmed that the anesthesia was effective, the dorsal fur on the right
and left sides was shaved with electric hair clippers. The shaved area
was disinfected with Isodine and a 70% ethanol-water solution and in-
cised to just below the muscle and peritoneum. The right and left ova-
ries were removed through the right and left surgical incisions. The
oviducts, together with surrounding adipose tissue, were ligated using
silk surgical sutures. The ovaries were separated and extirpated from
the surrounding tissue on the side peripheral to the ligated area. In
the sham operation, the skin of the animals was incised to just below
the muscle and peritoneum under the same anesthesia and the ovaries
were visually conﬁrmed; however, the ovaries were not separated or
extirpated. In each case, Ampicillin® (Meiji Seika Kaisha, Ltd.) (0.1 mL,
5 mg/site; 0.2 mL, 10 mg/body) was dropped intraperitoneally into
the incision site, and the musculature and peritoneum were sutured
concomitantly using nylon surgical sutures, and the coat was closed
with a clip. The clip was removed from all animals approximately
2 weeks after the operation.
2.10. Short term (4-week) preliminary study in OVX rats
In a short-term preliminary study using surgically OVX rats, the
groups were weight-matched before surgery. The rats were assigned
to the following seven groups of eight animals each: sham, OVX, or SI-
591 (0.26, 0.64, 1.6, 4, or 10 mg/kg). SI-591 was suspended in 0.5%
methylcellulose (vehicle). The sham group was sham-operated and
given vehicle equivalent to the volume administered to each experi-
mental group; the OVX group was ovariectomized and given vehicle;
and the SI-591 groups were ovariectomized and given various doses
of SI-591. All treatments were administered orally twice a day from
the day after the operation to the day before necropsy (total: 4 weeks).2.11. Long term (12-week) preliminary study in OVX rats
In a long-term preliminary study using surgically OVX rats, the
groups were weight-matched before surgery. The rats were assigned
to the following seven groups of twelve animals each: sham, OVX, or
SI-591 (0.25, 0.75, 2.2, 6.7, or 20 mg/kg). All groups were subjected to
the same procedures as described for the short-term preliminary
study. All treatments were administered orally once daily from the
day after the operation to the day before necropsy (total: 12 weeks).
2.12. Long term (12-week) exploratory study in OVX rats
In a long-term exploratory study using surgically OVX rats, the
groups were weight-matched before surgery. The rats were assigned
to the following ﬁve groups of twelve animals each: sham, OVX, or
SI-591 (4, 10, or 25 mg/kg). All groups were subjected to the same pro-
cedures as described above. All treatments were administered orally
twice a day for 3months from 3months post-surgery (total: 12 weeks).
2.13. Collection of samples
In all the OVX experiments, the rats were housed individually in
metabolic cages for 24 h on the day before necropsy for urine collection.
Urine samples were centrifuged (1700 g, 15min, 4 °C) and the superna-
tant was stored in a deep freezer until analysis. At necropsy, blood sam-
ples were drawn from the abdominal aorta under anesthesia with
Somnopentyl® (64.8 mg/kg; Kyoritsu Seiyaku, Tokyo, Japan). The
blood sampleswere centrifuged (1700 g, 15min, 4 °C) and the obtained
serum was stored in a deep freezer until analysis.
2.14. Measurement of bone markers
Urinary CTX-I concentrations were determined using a using
RatLaps™ ELISA kit (Nordic Bioscience Diagnostics A/S, Copenhagen,
Denmark) and measured by a multilabel counter. Urinary pyridinium
cross-links deoxypyridinoline (DPD) concentrations were measured
by a multilabel counter using an OSTEOLINKS-DPD EIA kit (Sumitomo
Seiyaku, Osaka, Japan). Serum BGP concentrations (ng/mL) were mea-
sured by a multilabel counter using an osteocalcin (bone Gla protein,
BGP) rat ELISA system (Amersham Pharmacia Biotech, Tokyo, Japan).
All measurements were performed according to the manufacturers'
instructions includedwith the kits. Urinary CTx andDPDexcretionmea-
surements were normalized to urine creatinine excretion.
2.15. Measurement of BMD
The lumbar vertebrae and right femurs were isolated from subject
rats and adherent tissue was removed. Bone mineral density (BMD)
measurements were performedwith dual energy X-ray absorptiometry
(DEXA) using the Bonemineral measurement system (DCS-600EX-IIIR,
Hitachi Aloka Medical, Ltd., Tokyo, Japan). The lumbar vertebrae and
right femur of each animal were set on the detection panel of the mea-
surement system with the spinous process and anterior sides facing
upward, respectively, and measured using the following parameters:
scan mode: clamp area scan; scan pitch: 1 mm; scan speed: high accu-
racy; and scan width: total width. Measurements were performed per
group in a single scan. The ROI (box type) of each bone was set on the
scanning screen and analyzed using the following parameters: analysis
method: DEXA; analysis threshold: R25; smoothing: 3; and ratio: stan-
dard ratio (3.122).
2.16. Statistical evaluation
All statistical analyses were performed using the SAS Preclinical
Package, Version 5.00.010720 (SAS Institute Japan, Osaka, Japan).
Table 1
Selectivity of SI-591 against other cathepsins.
Enzyme IC50 (nM) Fold (/Human Cat K)
Human Cathepsin K 1.4 1
Rat Cathepsin K 46 –
Human Cathepsin S 11 7.9
Human Cathepsin B 96 69
Human Cathepsin L 71 51
Fig. 2. Cellular effects of SI-591 on bone resorption in vitro. Cells were stained with TRAP
(A). SI-591 inhibits rat osteoclastic bone resorption in vitro (B). Rat osteoclast-like cells
were cultured on ivory slices with SI-591 in the presence of RANKL and M-CSF for
6 days. CTX-I was determined from the culture medium using a human-speciﬁc Cross
Laps ELISA assay. Data are presented as means (n = 3). *p b 0.05: signiﬁcantly different
from the control group (Dunnett's test).
Fig. 3. Effect of SI-591 on serum calcium concentrations in rats fed with a low calcium
diet. Rats fed with a low calcium diet for one week were administrated vehicle and
SI-591 (3–30 mg/kg) orally. Blood samples from the jugular vein were collected before
and at 4, 6, and 24 h after administration. The serum concentrations of calciumweremea-
sured sing the Calcium C-test. Values are themean+ SEM (n= 6). *p b 0.05, ***p b 0.001:
signiﬁcantly different from the control group (Dunnett's test).
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3.1. Inhibitory effect of SI-591 on various cathepsins
The effect of SI-591 on various cathepsins was investigated to com-
pare its selectivity by means of the IC50 (nM) value (at which activity
of each cathepsin was inhibited by 50%). SI-591 potently inhibited the
activity of human cathepsin K (IC50, 1.4 nM) and this inhibitory effect
was approximately 7.9-, 69-, and 59-fold higher than those on cathep-
sins S, B, and L, respectively (Table 1). Furthermore, SI-591more potent-
ly inhibited the activity of human cathepsin K compared with rat
cathepsin K.
3.2. Effect of SI-591 on rat osteoclast activity and bone resorption
Rat bone marrow cells were cultured with M-CSF and RANKL for
6 days in the presence of vehicle or SI-591. Cells cultured with M-CSF
and RANKL differentiated into large, multinucleated, and osteoclast-
like cells that showed numerous TRAP- and cathepsin K-positive cells
(Fig. 2A). SI-591 inhibited neither the formation of multinucleated
osteoclast (Fig. 2A) nor the viability of osteoclasts at concentrations of
0.01, 0.1, 1, and 10 μM (data not shown). SI-591 did not apparently af-
fect themorphology of the osteoclasts even at the highest concentration
(10 μM) (Fig. 2A).
Osteoclasts are known to secrete proteolytic enzymes that generate
CTX-I by degrading type I collagen in the ivory. Therefore, to measure
osteoclast activity, CTX-I in the culture supernatants was measured
with an ELISA kit. The results showed that SI-591 inhibited the release
of CTX-I in a concentration-dependent manner (Fig. 2B) with an IC50
of 3 μM, demonstrating that SI-591 has the ability to inhibit the bone
resorption.
3.3. Effect of SI-591 on serum calcium concentrations in rats fed a low cal-
cium diet
Rats were fed a low calcium diet for 7 days and then their serum cal-
cium concentration was measured, and determined not to have
changed from that prior to the low calcium diet (data not shown).
After 7 days, SI-591was administrated once at an oral dose of 0 (vehicle
alone), 3, 10, and 30 mg/kg. SI-591 signiﬁcantly reduced the serum cal-
cium level at 4 to 6 h after administration; the level retuned to that of
the control 24 h later (Fig. 3).
3.4. Effects of SI-591 preliminary treatment on bone loss in OVX rats
The preliminary effects of SI-591 on three parameters were investi-
gated in OVX rats. SI-591 was administrated twice daily at an oral dose
of 0 (vehicle alone), 0.26, 0.64, 1.6, 4, or 10 mg/kg for 4 weeks from the
day after OVX, followed by measurements of urinary CTX-I concentra-
tion, serum BGP concentration, and BMD. The concentration of urinary
CTX-I, a bone resorption marker, was signiﬁcantly increased in rats
4weeks after OVX (Fig. 4A). The concentration of serumBGP, a bone for-
mation marker, was also signiﬁcantly increased in OVX rats. However,
SI-591 had no effect on the OVX-induced increase of this marker at
the doses tested (Fig. 4B). BMD in the lumber vertebrae and right fe-
murs were signiﬁcantly decreased in OVX rats compared with sham-
Fig. 4. Effects of short term (4-week) SI-591 preliminary treatment on bone loss in OVX rats. The OVX female rats were allocated to 7 groups (8 animals/group) according to bodyweight:
sham, andOVX treatedwith vehicle or SI-591 (0, 0.26, 0.64, 1.6, 4, and 10mg/kg). Urinary CTX-I and serumBGP concentrationsweremeasured using ELISA kits. BMDmeasurementswere
performed with DEXA. Values are the mean + SEM (n= 8), *p b 0.05, ***p b 0.001: signiﬁcantly different from the sham group (Student's t-test), ##p b 0.01 ###p b 0.001: signiﬁcantly
different from the OVX rat not receiving SI-591 group (Dunnett's test). Sham, sham operated; p.o., per os; b.i.d., bis in die.
431T. Fujii et al. / Bone 81 (2015) 427–434operated rats (Fig. 4C and D), and SI-591 signiﬁcantly inhibited the
OVX-induced decrease in BMD in a dose-dependent manner. In con-
trast, SI-591 had no obvious effect on body weight at the doses tested
in the OVX rats (data not shown).
In another experiment, SI-591 was administrated once daily at an
oral dose of 0 (vehicle alone), 0.25, 0.75, 2.2, 6.7, or 20 mg/kg for
12weeks from the day after OVX, followed bymeasurements of urinary
DPD concentration, serum BGP concentration, and BMD.
BMD concentrations in the lumber vertebrae and right femurs were
signiﬁcantly decreased in OVX rats compared with sham-operated rats
(Fig. 5C and D), and SI-591 signiﬁcantly inhibited this decrease at
doses of 2.2 mg/kg and above.Fig. 5. Effects of long term (12-week) SI-591 preliminary treatment onbone loss inOVX rats. The
sham, and OVX treatedwith vehicle or SI-591 (0.25, 0.75, 2.2, 6.7, and 20mg/kg). Urinary DPD
performedwith DEXA. Values are themean+ SEM (n=12), *p b 0.05, **p b 0.01: signiﬁcantly
OVX rat not receiving SI-591 group (Williams' test). Sham, sham operated; p.o., per os; s.i.d., seThe bone resorption and formation markers DPD were found to
show similar tendencies as those seen during short term study
(Figs. 4A and B and 5A and B). However, SI-591 had no obvious effect
on body weight even after 12 week administration in OVX rats (data
not shown).
3.5. Effects of SI-591 exploratory treatment on bone loss in OVX rats
The exploratory effects of SI-591 on OVX rats were investigated.
SI-591 was administrated twice daily at an oral dose of 4, 10, or
25 mg/kg for 12 weeks starting 12 weeks after OVX. Urinary DPD con-
centration, serum BGP concentration, and BMD were measured at theOVX female ratswere allocated to 7 groups (12 animals/group) according to bodyweight:
and serum BGP concentrations weremeasured using ELISA kits. BMDmeasurements were
different from the sham group (Student's t-test), #p b 0.05: signiﬁcantly different from the
mel in die.
Fig. 6. Effects of long term (12-week) SI-591 exploratory treatment on bone loss inOVX rats. TheOVX female ratswere allocated to 5 groups (12 animals/group) according to bodyweight:
sham, and OVX treated with vehicle or SI-591 (4, 10, and 25 mg/kg). Urinary DPD and serum BGP concentrations were measured using ELISA kits. BMD measurements were performed
withDEXA. Values are themean+SEM(n=12), **p b 0.01: signiﬁcantly different from the shamgroup (Student's t-test), #p b 0.05, ##p b 0.01: signiﬁcantly different from theOVX rat not
receiving SI-591 group (Williams' test). Sham, sham operated; p.o., per os; b.i.d., bis in die.
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markers were found to maintain the levels that were seen at 12 weeks
after OVX (Figs. 5 and 6). SI-591 signiﬁcantly inhibited the OVX-
induced decrease in BMD at doses of 10 mg/kg and above. In contrast,
SI-591 had no effect on the concentration of serum BGP (Fig. 6B), a
bone formation marker, or body weight (data not shown).
4. Discussion
The primary aim of this study was to identify a compound that
showed the efﬁcacy of current therapies for osteoporosis without the
associated AEs. Therefore, SI-591 was synthesized as one of several
unique peptidomimetic compounds without a basic group to avoid
AEs. The reasons we avoid using basic group, we know that the pH is
low in the liposome localized cathepsins. Therefore, we avoided using
basic groups with formed salt structures in the low pH condition.
We evaluated the in vitro and in vivo pharmacological effects of
SI-591, and found it to be a potent inhibitor of human and rat cathepsin
K. SI-591 inhibited human cathepsin K with nanomolar potency and
was from 7.9 to 69 times more selective for cathepsin K than for other
cysteine cathepsin subtypes.
We further examined the effects of SI-591 treatment by incorporat-
ing the bone resorption assay, which is widely utilized to evaluate bone
resorption in vitro. In this assay, osteoclasts are induced from bone
marrow cells or synovial cells using several cytokines (GM-CSF and/or
RANKL) applied to a bone slice. For evaluation, the osteoclast release
of bone resorption markers (CTx and NTx) is measured by ELISA. In
the current study, the bone resorption assay demonstrated that SI-591
directly inhibited rat osteoclast-mediated bone resorption. Additionally,
it was found that SI-591 treatment evinced no cytotoxic effects such as
bisphosphonate-induced osteoclast apoptosis [26,27], and resulted in
no obvious differences in cell morphology or TRAP or cathepsin K stain-
ing. These results suggest that SI-591 did not inﬂuence the viability and
formation of osteoclasts.
One of themajor obstacles hampering the development of new ther-
apeutic agents is themarked inter-species difference in sites such as the
catalytic sites of cathepsin K, as has been reported between humans and
rats [28]. However, SI-591 inhibited human cathepsin K activity with
approximately nanomolar potency and its inhibition in rats was only39-fold less than that of the human enzyme. In addition, SI-591 dose-
dependently (0.001–10 μM) suppressed bone resorption by rat bone
marrow-derived osteoclasts.
To further examine the bone resorption inhibitory capabilities of
SI-591, we analyzed its effects in a low-calcium background. A low
calcium diet has been reported to increase bone remodeling in several
animal models [29–31]. Generally, the serum calcium concentration is
tightly controlled by a complex homeostatic mechanism involving
ﬂuxes of calcium between the extracellular ﬂuid and the kidneys, the
bones, and the gut [32]. It is thought that mobilization of calcium from
the bones is required to maintain normal blood calcium levels in these
calcium-deprived rat models. In rats fed a low calcium diet, SI-591
suppressed serum calcium concentrations by inhibiting cathepsin K ac-
tivity. Suppressive effects of SI-591 at 3 mg/kg on serum calcium levels
were observed for up to 6 h; these then recovered to normal levels
by 24 h after administration. These results demonstrate that SI-591
exhibits an early onset of inhibition of bone resorption activity and a
relatively short duration of action in rats.
In the normal state, bone formation and resorption are closely
linked. However, in osteoporosis, there is an imbalance such that re-
sorption exceeds formation. The OVX rat model is widely known to de-
velop osteopenia with declining levels of systemic estrogen after
ovariectomy, not unlike postmenopausal women. This model has been
used to evaluate various existing and novel treatments for osteopenia,
and the efﬁcacy of new therapies can bemonitored using bone turnover
markers and BMD. Therefore, the OVX rat model is recommended
by the Federal Drug Administration (FDA) for evaluating therapeutic
effects in bone-loss prevention with underlying estrogen depletion
[33–36].
In accordancewith this recommendation, we therefore examined the
effects of SI-591 in the OVX model. The bone resorption markers used
in this study were the well-known factors TRAP; products that break-
down collagen such as pyridinium cross-links, pyridinoline (PYD), and
deoxypyridinoline (DPD); galactosyl hydroxylysine (GHYL); and cross-
linked telopeptides (CTx and NTx). Thesemarkers have been extensively
used to assess the risk of fracture, assess bone loss, or monitor response
to antiresorptive therapy [37]. In this report, the CTX-I and DPD bone re-
sorptionmarkers weremeasured to examine the effects of SI-591. SI-591
signiﬁcantly suppressed the OVX-induced increase in bone resorption
433T. Fujii et al. / Bone 81 (2015) 427–434markers in the three studies. Bone biochemical markers are increasingly
used for early assessment of the response to therapy for osteoporosis.
However, these marker tests cannot replace BMD testing to monitor
long-term exploratory effects, because in humans, BMD changes several
percent per year,whereas the bone turnovermarkers rapidly change sev-
eral dozen percent per week, after the initiation of antiresorptive treat-
ment [38,39]. For that reason, we evaluated BMD loss at the lumbar
vertebrae and the femurs in the three studies. The results demonstrated
that SI-591 signiﬁcantly suppressed BMD loss in the lumbar vertebrae
and the femurs in both types of studies. In the exploratory study over
12 weeks, lumbar vertebrae and femur BMDs were increased by a maxi-
mum of approximately 4%.
On the other hand, SI-591 did not affect the bone formation marker
serum BGP in this report. In contrast, the potent nitrogen-containing
bisphosphonates, such as zoledronic acid and alendronate, are widely-
prescribed medications for the treatment of osteoporosis and are
known to inhibit not only bone resorption but also bone formation
in vivo. In long-term alendronate therapy, low-energy subtrochanteric
fractures were found in nine women [40], making the atypical femoral
fractures associated with long-term bisphosphonates a growing con-
cern [41]. It has been reported that suppression of bone remodeling by
bisphosphonates might lead to a failure to repair microdamage. Addi-
tionally, treatment with denosumab, a fully humanizedmonoclonal an-
tibody against RANKL, also leads to marked suppression of bone
formation markers in human [42,43]. Denosumab has also been associ-
ated with increased risk of osteonecrosis of the jaw [44], which has also
been seen with bisphosphonates [45,46]. Unlike these other com-
pounds, in vivo data from this report showed that SI-591, in contrast,
did not affect the coupling of bone resorption and formation.
Odanacatib is a highly speciﬁc compound and has shown encourag-
ing results in both non-clinical and clinical studies. However, Merck
voiced some concerns regarding its safety proﬁle, more speciﬁcally the
development of morphea as a cutaneous side effect of the treatment.
SI-591 is a more neutral compound than balicatib and odanacatib as
shown by the Admet Predictor™ Version 3.0.0003 (Simulations Plus,
Inc., Lancaster, CA). The results suggest that SI-591 salt formation at
pH values lower than 7 is unlikely to occur, contrary to the other cathep-
sin K inhibitors. Therefore, we believe that the risk of developing
morphea is lower in the treatment with SI591 than with the other two
compounds.
Taken together, these data suggested that the safe, potent, and selec-
tive cathepsin K inhibitor, SI-591, can be effective in preventing bone
loss in vitro and in vivo and might be therapeutically beneﬁcial in the
treatment of diseases with accelerated bone loss such as postmeno-
pausal osteoporosis.Acknowledgments
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